retatrutide phase 2 trial results obesity in 28 percent average weight loss Retatrutide: The Triple Agonist That's

VYEPTI (eptinezumab-jjmr) represents the cutting edge of migraine treatment

While no large prospective studies have quantified SIBO incidence, the theoretical mechanism is plausible: prolonged small bowel transit time allows bacterial proliferation, producing bloating, pain, and diarrhea that mimics or worsens IBS-D

Among individuals with overweight or obesity, calculating the recommended protein intake using their actual bodyweight may lead to a significant overestimation of protein requirement

Washington Post

The health risks are not trivial

My focus is sharper, my sleep is better, and I finally feel in control of my body and health